Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals, Inc. has agreed to be acquired by Vertex Pharmaceuticals Incorporated through a merger in which Vertex’s wholly owned subsidiary, Clark Merger Sub, Inc., will merge with and into Crinetics. At closing, each share of Crinetics common stock will be converted into the right to receive $85.00 in cash per share, without interest and subject to withholding taxes, unless appraisal rights are properly exercised under Section 262 of the DGCL.
Crinetics’ board unanimously determined the merger and related transactions are fair and in the best interests of shareholders, approved the Merger Agreement dated July 6, 2026, and recommends voting FOR the merger proposal, the advisory compensation proposal, and the adjournment proposal. Completion requires approval by holders of at least a majority of outstanding shares entitled to vote and satisfaction of regulatory and other conditions. If the merger is not completed, Crinetics will remain an independent public company, and in certain termination scenarios it must pay Vertex a $350,474,425 cash termination fee.
Crinetics Pharmaceuticals, Inc. describes new Non-Compete Agreements entered into on July 6, 2026 with key employees in connection with its previously announced Merger Agreement with Vertex Pharmaceuticals Incorporated. The merger will combine Crinetics with a wholly owned Vertex subsidiary, with Crinetics surviving as a wholly owned subsidiary of Vertex.
Under these Non-Compete Agreements, Crinetics’ President and CEO R. Scott Struthers, CFO Tobin Schilke, Chief Scientific Officer Stephen Betz, and Chief Commercial Officer Isabel Kalofonos agree that for one year immediately following the merger closing date they will not perform services in any capacity for specified restricted businesses in territories where Crinetics conducts business as of closing. In consideration for these commitments, on the merger closing date Mr. Schilke, Dr. Betz and Ms. Kalofonos will receive cash payments of $140,000, $30,000 and $30,000, respectively.
The report also includes extensive forward-looking statement disclosures and outlines that Crinetics plans to file preliminary and definitive proxy statements so its stockholders can vote on approval of the proposed transaction with Vertex.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share. The trade occurred on July 2, 2026 and was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, he directly holds 19,225 Crinetics shares.
Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals in an all-cash merger. Crinetics stockholders will receive $85.00 per share in cash, implying a total equity value of approximately $10.0 billion, or about $8.8 billion net of estimated cash acquired.
At closing, Crinetics will become a wholly owned Vertex subsidiary. All unvested Crinetics stock options and restricted stock units will fully vest, with in-the-money awards converted into cash based on the $85.00 price; underwater options will be canceled. The deal is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval, antitrust and other regulatory clearances, and customary closing conditions, and is not subject to a financing condition.
Jeff Knight reports proposed dispositions of Common Stock and recent 10b5-1 sales. The filing lists 44,925 shares tied to an Exercise of Stock Options with a proposed sale date of 07/02/2026 and 2,495 Restricted Stock Units dated 03/15/2025. The excerpt also shows 10b5-1 sales totaling 120,982 shares across 04/08/2026–05/04/2026 with proceeds reported in the filing.
Crinetics Pharmaceuticals director Caren Deardorf received new equity awards in the form of restricted stock units and stock options. She was granted 5,925 restricted stock units, representing the right to receive the same number of common shares, which vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service.
She was also granted stock options covering 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. Following these awards, she directly holds 22,225 shares of common stock, in addition to the new option position.
Crinetics Pharmaceuticals director Matthew K. Fust received new equity awards as board compensation. He was granted 5,925 restricted stock units representing common shares at no purchase price, increasing his direct holdings to 28,761 common shares after the award.
Fust was also granted stock options for 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and options vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual shareholder meeting, subject to his continued board service.
Crinetics Pharmaceuticals director Nichols Weston received new equity awards. The filing shows a grant of 5,925 shares of common stock in the form of restricted stock units, bringing his direct common share holdings to 22,225. He was also granted a stock option over 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual meeting of stockholders, subject to his continued service on the board.
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio received equity compensation on June 18, 2026. He was granted 5,925 shares of Common Stock in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service. He also received options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, vesting on the same schedule and expiring on June 18, 2036. Following these grants, he directly holds 22,225 Common Shares and 9,730 stock options.